Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. Matricelf Ltd was incorporated in 2019 and is based in Ness Ziona, Israel.
Metrics to compare | MTLF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMTLFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.8x | −2.8x | −0.4x | |
PEG Ratio | 0.07 | −0.04 | 0.00 | |
Price/Book | 10.5x | 1.7x | 2.6x | |
Price / LTM Sales | - | 2.7x | 3.1x | |
Upside (Analyst Target) | - | 915.3% | 56.0% | |
Fair Value Upside | Unlock | −1.1% | 9.0% | Unlock |